BLTE

Belite Bio

Fundamental data last updated:April 13, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

Nasdaq

County of HQ

United States

Next Earnings Date

05/12/26

Business Summary

Belite Bio operates as a biotechnology developer focused on therapeutics within the Healthcare sector, monetizing through the advancement of proprietary drug candidates toward regulatory approval and commercialization. The business model is capital-intensive and driven by research and development, where value creation hinges on successful clinical outcomes that unlock licensing deals or product sales. Competitive advantage in this space comes from intellectual property protection, scientific specialization, and regulatory exclusivity rather than scale economics. Cash generation ultimately depends on converting pipeline assets into approved therapies that can command premium pricing within targeted disease markets.

 


Analyze BLTE on TradingView

VALUATION

P/E

-

Market Cap ($M USD)

$6,904

Forward P/E

220.1

PEG

-

PRICE TO SALES

-

PRICE TO BOOK

9

EV / EBITDA

-83.1

5-Year Average P/E

Free Cash Flow Yield

DCF Value

Graham Number

Price to FCF

EV to FCF

Earnings Yield

FCF Yield

DIVIDEND

Yield

-

Annual Payout

-

Payout Ratio

-

Consecutive Years of Dividend Growth

0

5-Year Dividend Growth Rate

-

Financial Health & Profitability

Earnings Per Share

-$2.31

Next Year EPS Growth Estimate

$0.79

Next Year Revenue Growth Estimate

628.00%

Return on Equity (ROE)

-10.10%

FREE CASH FLOW

Operating Margin

-

Debt-to-Equity

0

Piotroski F-Score

3

Altman Z-Score

411.4

Return on Invested Capital (ROIC)

-18.40%

Current Ratio

50

Quick Ratio

Net Debt to EBITDA

Interest Coverage

Gross Profit margin

FCF PER SHARE

REVENUE PER SHARE

Analyze BLTE on TradingView

Gainseekers Quantitative Analysis

Summary

At a $6,904M market cap with no trailing P/E and a Forward P/E of 220.1, BLTE is priced purely on distant expectations, not present fundamentals. EPS of -83.1, projected EPS next year of -$2.31, ROIC of -18.40%, and an operating margin of -10.10% confirm this is a capital-consuming operation, not a cash generator. However, the Altman Z-Score of 411.4 and a Current Ratio of 50 signal extraordinary balance sheet safety, implying negligible near-term solvency risk. This is not mispriced as a value stock — it is priced as a high-conviction growth optionality play where investors are paying an extreme premium for future breakthroughs while being insulated from bankruptcy risk.

AI Exposure / Tech Reliance

As a Biotechnology company within Healthcare, BLTE operates in a research-intensive field that increasingly leverages AI for drug discovery, trial design, and molecular modeling. The sector is structurally aligned with data-driven innovation, which can compress development timelines and improve target identification. While no specific AI metrics are provided, the industry positioning naturally supports technological adaptability.

The Bull Case

A GARP-oriented investor could justify ownership based on financial survivability and optionality. The Altman Z-Score of 411.4 and Current Ratio of 50 indicate fortress-level liquidity, meaning dilution or distress risk is materially lower than typical early-stage biotech peers. Despite a weak Piotroski F-Score of 3, the company maintains a positive Return on Equity of 628.00%, which, in combination with institutional ownership listed at $211.50 and a Consensus Rating of 4.60%, suggests sophisticated capital is willing to underwrite ongoing losses in anticipation of inflection. Sales Growth Next Year of $0.79, while modest in absolute terms, signals forward commercial traction that could justify today’s premium if operating leverage materializes.

The Bear Case

The bear case is straightforward and brutal: a Forward P/E of 220.1 with a PEG Forward of "-" and Price / Sales of "-" means investors lack traditional valuation anchors. EPS of -83.1, projected EPS next year of -$2.31, ROIC of -18.40%, and an operating margin of -10.10% demonstrate structural unprofitability with negative capital efficiency. Debt / Equity and Short % of Float are not provided, leaving uncertainty around leverage structure and bearish positioning, which increases opacity. With a Piotroski F-Score of 3, fundamental quality is weak, and without earnings visibility, any clinical or regulatory setback could compress valuation multiples violently.

Market Sentiment & Smart Money

Short Interest %

4.60%

Analyst Consensus

1.22

Average Analyst Price Target

$211.50

Institutional Ownership %

18.50%

1-Year Beta

0.86

Insider Buying % (6 Mo)

43.90%%

Distance to 52-Week High

86.40%

Distance to 52-Week Low

322.30%

EARNINGS SURPRISE %

50-DAY SMA

200-DAY SMA

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.